Your browser doesn't support javascript.
loading
Cardiotoxicities of Novel Therapies in Hematological Malignancies: Monoclonal Antibodies and Enzyme Inhibitors.
Prathivadhi-Bhayankaram, Sruti; Abbasi, Muhannad Aboud; Ismayl, Mahmoud; Marar, Rosalyn I; Al-Abcha, Abdullah; El-Am, Edward; Ahmad, Ali; Acevedo, Andres Daryanani; Ellauzi, Rama; Villarraga, Hector; Paludo, Jonas; Anavekar, Nandan.
Afiliação
  • Prathivadhi-Bhayankaram S; Division of Internal Medicine, University of Iowa Healh Care, Iowa City, IA.
  • Abbasi MA; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic address: abbasi.muhannad@mayo.edu.
  • Ismayl M; Division of Internal Medicine, Creighton University, Omaha, NE.
  • Marar RI; Division of Internal Medicine, University of Nebraska Medical Center, Omaha, NE.
  • Al-Abcha A; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
  • El-Am E; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
  • Ahmad A; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
  • Acevedo AD; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
  • Ellauzi R; Division of Internal Medicine, Henry Ford Hospital, Detroit, MI.
  • Villarraga H; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
  • Paludo J; Division of Hematology-Oncology, Mayo Clinic, Rochester, MN.
  • Anavekar N; Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Curr Probl Cardiol ; 48(8): 101757, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37094764
Monoclonal antibodies (mAB) selectively target leukemia surface antigens and work by either blocking cell surface receptors or triggering the target cell's destruction. Similarly, enzyme inhibitors bind to complex molecular platforms and induce downstream mechanisms that trigger cell death. These are used in a variety of hematologic malignancies. Yet, they also elicit severe immune-mediated reactions as biological agents that require careful monitoring. Cardiovascular effects include cardiomyopathy, ventricular dysfunction, cardiac arrest, and acute coronary syndrome. While there have been scattered reviews of mAB and enzyme inhibitors, a consolidated resource regarding their cardiovascular risk profile is lacking. We provide general recommendations for initial screening and serial monitoring based on the literature.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Anticorpos Monoclonais Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Anticorpos Monoclonais Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article